Torin2: From mTOR Inhibition to Cell Death
2026-09-17
A translational framework for using Torin2 to connect mTOR pathway suppression with apoptosis, transcription-independent cell death, model selection, and preclinical decision-making.
Moxidectin Potentiates Polyenes Against Oral Candidiasis
2026-09-16
The 2024 study shows that Moxidectin enhances amphotericin B and nystatin activity against Candida albicans by increasing fungal ergosterol biosynthesis and polyene binding. Combination treatment also reduced oral infection burden and mucosal inflammation in mice, supporting Moxidectin as a research candidate for polyene potentiation rather than as an established antifungal therapy.
LINC01977, Super-Enhancers, and SMAD3 in LUAD
2026-09-15
Zhang et al. identify a super-enhancer-driven LINC01977–SMAD3 circuit that links tumor-associated macrophage signals with malignant behavior in early-stage lung adenocarcinoma. The study combines epigenomic, chromatin-contact, functional, and in vivo evidence, providing a mechanistic framework for investigating canonical TGF-β signaling in tumor progression and related disease models.
mRNA Vaccine Protection Against H5N1 in Dairy Cows
2026-09-15
The reference study evaluates a hemagglutinin-based mRNA–lipid nanoparticle vaccine in high-yielding lactating dairy cows, addressing a major translational gap between experimental mRNA platforms and protection in a relevant livestock host. The vaccine was well tolerated, induced strong antibody responses, protected all immunized cattle after a high-dose H5N1 challenge, and retained substantial protection when serum antibody levels had declined.
Deferasirox Fe3+ Chelate in Myeloid Research
2026-09-14
This practical guide shows how to use Deferasirox Fe3+ chelate in iron, mitochondrial ROS, and myeloid differentiation workflows. It emphasizes chemical-form controls, oxygen-aware experimental design, and troubleshooting strategies that distinguish ferric-complex effects from free deferasirox activity.
Ivermectin Research Workflows for Parasitology
2026-09-14
Build mechanism-first parasite assays with Ivermectin by combining controlled solvent handling, motility readouts, viability measurements, and host-cell counterscreens. This guide also explains how findings from Gasdermin C research can inform assay design without overstating an unproven oncology application.
Vorinostat Workflows for HDAC and Apoptosis Research
2026-09-13
Build reproducible HDAC-inhibition experiments with Vorinostat, from concentration–response design to orthogonal apoptosis confirmation. The workflow also shows how the reference study’s live-cell HO-1 activity imaging can support a carefully controlled, hypothesis-generating extension into epigenetic regulation.
DAMGO: A Causal Probe of Opioid Pain Biology
2026-09-12
DAMGO is a selective µ-opioid receptor agonist for connecting receptor activation with tissue responses and pain behavior. This article presents an assay-centered framework for interpreting MOR signaling, mechanical hypersensitivity, and tolerance without conflating distinct experimental scales.
Antiarrhythmic Drugs and KCa2 Channels in AF
2026-09-12
The reference study systematically tested clinically used antiarrhythmic drugs against human KCa2.2 and KCa2.3 channels using automated whole-cell patch clamp. Dofetilide and propafenone inhibited these channels, whereas the potency gap relative to therapeutic exposure suggests that KCa2 inhibition is unlikely to explain their clinical antiarrhythmic actions.
LIRP Enables Light-Controlled Gene Therapy
2026-09-11
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translation-initiation stage. In mouse models, LIRP-regulated AAV2 systems enabled light-dependent metabolic intervention and reversible control of retinal VEGF inhibition, illustrating a potential safety framework for regulated gene therapy.
Ivermectin Assay Design: From Dose to Readout
2026-09-11
Ivermectin assay design requires more than selecting a concentration: solvent control, parasite stage, exposure duration, and orthogonal endpoints all shape interpretation. This guide combines rigorous anti-parasitic research practice with assay lessons from a pivotal GSDMC pancreatic cancer study, without overstating cross-domain evidence.
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-10
This FASEB Journal study presents chemically modified p21 mRNA packaged in lipid nanoparticles for localized intravesical treatment of bladder cancer. The work connects bladder-restricted delivery with tumor-suppressor restoration, cell-cycle inhibition, DNA-damage signaling, and reduced systemic exposure, while also defining important preclinical limitations.
Firefly Luciferase mRNA: Reliable Cell Assays
2026-09-10
Learn how EZ Cap™ Firefly Luciferase mRNA (5-moUTP), SKU R1013, can improve reporter-based cell viability, proliferation, and cytotoxicity workflows through defined capping, nucleotide modification, and handling practices. This scenario-driven guide connects transcript design, delivery controls, signal interpretation, and practical product selection.
Amplex Red Workflows for H2O2 Assays
2026-09-09
Amplex Red converts hydrogen peroxide into a fluorescent resorufin signal, supporting sensitive enzyme, cell, mitochondrial, and protein-engineering workflows. The reference study shows how an improved peroxidation format can move beyond routine ROS measurement into rapid screening of peroxide-dependent cytochrome P450 variants.
Thrombin B Chain Fragment Assay Workflows
2026-09-09
Build more reliable thrombin research workflows with a defined 17-residue B-chain fragment for peptide standards, binding studies, immunoassay controls, and LC-MS method development. Because this reagent is not intact active thrombin, it is especially valuable as a specificity control alongside functional coagulation assays.